Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA issues guidance on product classification codes and molecular diagnostic instruments with combined functions. More regulatory news.

You may also be interested in...



Regulatory News In Brief

Physician Payment Sunshine Act finally goes to OMB. FDA signs regulatory agreements with Brazil, Australia and Canada. More regulatory news.

Could Changing Alarm Default Settings Allay Nurse "Alarm Fatigue?" AAMI Thinks So

The Association for the Advancement of Medical Instrumentation is considering a project to set medical device alarm default parameters. The goal: to reduce alarm fatigue among doctors and nurses.

Regulatory News In Brief

FDA issues draft guidance on classification product codes. Black box warning required for ovarian adnexal mass test systems. More regulatory news.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel